KR20150100716A - 항 인간 b7-h4 항체 및 이의 용도 - Google Patents

항 인간 b7-h4 항체 및 이의 용도 Download PDF

Info

Publication number
KR20150100716A
KR20150100716A KR1020157017826A KR20157017826A KR20150100716A KR 20150100716 A KR20150100716 A KR 20150100716A KR 1020157017826 A KR1020157017826 A KR 1020157017826A KR 20157017826 A KR20157017826 A KR 20157017826A KR 20150100716 A KR20150100716 A KR 20150100716A
Authority
KR
South Korea
Prior art keywords
antibody
human
tumor
molecule
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157017826A
Other languages
English (en)
Korean (ko)
Inventor
솔로몬 랭거만
린다 리우
생 야오
라이핑 첸
마이클 글렌 오버스트리트
Original Assignee
앰플리뮨, 인크.
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앰플리뮨, 인크., 더 존스 홉킨스 유니버시티 filed Critical 앰플리뮨, 인크.
Publication of KR20150100716A publication Critical patent/KR20150100716A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
KR1020157017826A 2012-12-19 2013-12-19 항 인간 b7-h4 항체 및 이의 용도 Withdrawn KR20150100716A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261739272P 2012-12-19 2012-12-19
US201261739287P 2012-12-19 2012-12-19
US201261739353P 2012-12-19 2012-12-19
US61/739,353 2012-12-19
US61/739,272 2012-12-19
US61/739,287 2012-12-19
PCT/US2013/076701 WO2014100483A1 (en) 2012-12-19 2013-12-19 Anti-human b7-h4 antibodies and their uses

Publications (1)

Publication Number Publication Date
KR20150100716A true KR20150100716A (ko) 2015-09-02

Family

ID=49917300

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157017826A Withdrawn KR20150100716A (ko) 2012-12-19 2013-12-19 항 인간 b7-h4 항체 및 이의 용도

Country Status (13)

Country Link
US (1) US9574000B2 (enExample)
EP (2) EP2934575A2 (enExample)
JP (2) JP2016509582A (enExample)
KR (1) KR20150100716A (enExample)
CN (1) CN104955475A (enExample)
AU (2) AU2013361231A1 (enExample)
BR (1) BR112015014063A2 (enExample)
CA (2) CA2894689A1 (enExample)
HK (1) HK1210027A1 (enExample)
MX (1) MX2015007846A (enExample)
RU (1) RU2015129551A (enExample)
SG (1) SG11201504764SA (enExample)
WO (2) WO2014100483A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170061152A (ko) * 2014-09-28 2017-06-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
US11713487B2 (en) 2017-07-14 2023-08-01 The Regents Of The University Of California Methods of predicting transplant rejection risk

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145568A1 (en) 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Antibodies to human b7x for treatment of metastatic cancer
CA2845536A1 (en) * 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
EP2773651B1 (en) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
AU2014244424A1 (en) 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
ITMI20130692A1 (it) 2013-04-26 2014-10-27 Copan Italia Spa Dispositivo e procedimento per il processamento automatico di piastre di coltura per campioni microbiologici
HRP20201906T1 (hr) 2013-12-20 2021-04-02 Fred Hutchinson Cancer Research Center Označene kimerne efektorske molekule i njihovi receptori
CN113698485A (zh) * 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
WO2016070001A1 (en) * 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
JP2018518151A (ja) * 2015-03-27 2018-07-12 ユニバーシティ オブ サザン カリフォルニア Ｂ７−ｈ４発現充実性腫瘍を処置するためのｃａｒ ｔ細胞
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
AU2016257929B2 (en) 2015-05-04 2022-10-20 Cytomx Therapeutics, Inc Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
KR102346988B1 (ko) 2016-07-26 2022-01-03 시즈오카켄 항 b7-h4 항체
WO2018058002A1 (en) 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
BR112019018863A8 (pt) 2017-03-15 2023-05-02 Hutchinson Fred Cancer Res Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
US11932694B2 (en) 2017-04-19 2024-03-19 Bluefin Biomedicine, Inc. Anti-VTCN1 antibodies and antibody drug conjugates
KR102641269B1 (ko) 2017-05-24 2024-02-26 이펙터 테라퓨틱스, 인크. 개선된 항종양 면역 반응을 위한 조성물 및 방법
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
US10814011B1 (en) 2017-06-16 2020-10-27 Nantbio, Inc. Anti-B7-H4 antibodies and methods
US11220544B2 (en) * 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
MX2020001287A (es) 2017-08-11 2020-08-20 Hutchinson Fred Cancer Res Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
UA128472C2 (uk) 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-h4 антитіла і методи їх використання
US20200262894A1 (en) 2017-09-06 2020-08-20 Fred Hutchinson Cancer Research Center Strep-tag specific binding proteins and uses thereof
CN111065410A (zh) 2017-09-06 2020-04-24 弗雷德哈钦森癌症研究中心 用于改善过继细胞疗法的方法
WO2019051128A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center SPECIFIC STREP LABEL CHIMERIC RECEPTORS AND USES THEREOF
EP3697435A1 (en) 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20200112913A (ko) * 2018-01-23 2020-10-05 넥스트큐어 인코포레이티드 B7-h4 항체 및 그 사용 방법
CN110366560B (zh) * 2018-02-11 2023-07-28 江苏豪森药业集团有限公司 抗b7-h4抗体、其抗原结合片段及其医药用途
CA3090700A1 (en) 2018-02-12 2019-08-15 Fred Hutchinson Cancer Research Center Cyclin a1 specific t cell receptors and uses thereof
CN111868089B (zh) * 2018-02-21 2025-08-22 戊瑞治疗有限公司 B7-h4抗体给药方案
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091138A1 (en) 2018-02-26 2019-08-29 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
CA3091801A1 (en) * 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
US20210221894A1 (en) * 2018-04-03 2021-07-22 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
US11440967B2 (en) 2018-05-31 2022-09-13 Glyconex Inc. Therapeutic antibodies
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
JP2021534752A (ja) 2018-08-22 2021-12-16 フレッド ハッチンソン キャンサー リサーチ センター Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法
WO2020068702A1 (en) 2018-09-24 2020-04-02 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
WO2020097530A2 (en) 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center Immunotherapy targeting mesothelin
US12304946B2 (en) 2018-12-19 2025-05-20 Humabs Biomed Sa Antibodies that neutralize hepatitis B virus and uses thereof
WO2020140070A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-b7-h4 binding proteins and methods of use thereof
GB2596461B (en) 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
US12448430B2 (en) 2019-03-11 2025-10-21 Fred Hutchinson Cancer Center High avidity WT1 T cell receptors and uses thereof
WO2020187327A1 (en) * 2019-03-21 2020-09-24 Suzhou Kanova Biopharmaceutical Co. Ltd. Anti-b7s1 polypeptides and their use
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4017872A1 (en) 2019-08-20 2022-06-29 Fred Hutchinson Cancer Center T-cell immunotherapy specific for wt-1
NZ785788A (en) 2019-08-29 2025-09-26 Vir Biotechnology Inc Antibody compositions and methods for treating hepatitis b virus infection
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN115643806A (zh) * 2020-01-31 2023-01-24 璟尚生物制药公司 双特异性t细胞接合器
AR122722A1 (es) 2020-06-24 2022-09-28 Vir Biotechnology Inc Anticuerpos que neutralizan el virus de la hepatitis b y sus usos
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
EP4155320A4 (en) * 2020-06-30 2024-03-27 Nona Biosciences (Suzhou) Co., Ltd. ANTI-B7H4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USE THEREOF
US20240383983A1 (en) 2020-08-18 2024-11-21 Abl Bio, Inc. Anti-B7-H4/Anti-4-1BB Bispecific Antibodies And Use Thereof
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
WO2022066965A2 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting sox2 antigens
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
WO2022132836A2 (en) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
KR20230137339A (ko) 2021-01-04 2023-10-04 메르사나 테라퓨틱스, 인코포레이티드 B7h4-표적화된 항체-약물 접합체 및 이의 사용 방법
US20240092872A1 (en) 2021-01-26 2024-03-21 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
US20240199750A1 (en) 2021-03-26 2024-06-20 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
KR20240019297A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2023288281A2 (en) 2021-07-15 2023-01-19 Fred Hutchinson Cancer Center Chimeric polypeptides
IL313159A (en) 2021-12-01 2024-07-01 Kadmon Corp Llc B7-H4 antibodies and ANTI-B7-H4 antibody/IL-15 fusion proteins
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AR129399A1 (es) 2022-05-23 2024-08-21 Vir Biotechnology Inc Anticuerpos diseñados neutralizantes del virus de la hepatitis b y usos de los mismos
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
KR20250129802A (ko) 2023-01-09 2025-08-29 프로타라 쎄라퓨틱스 인코포레이티드 삼중 음성 유방암 및 비-근육 침습성 방광암 치료를 위한 Streptococcus pyogenes의 비생존 세포와 면역 관문 억제제의 조합
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
NZ251628A (en) 1992-03-30 1996-07-26 American Home Prod Aqueous insectable rapamycin solution; product containing concentrate and diluent solutions
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CH686365A5 (de) 1992-10-06 1996-03-15 Werner Hofliger Mobilkran.
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
SG64372A1 (en) 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5942328A (en) 1996-02-29 1999-08-24 International Business Machines Corporation Low dielectric constant amorphous fluorinated carbon and method of preparation
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US5843597A (en) 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
US6982323B1 (en) 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
CA2341142A1 (en) 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
FR2844455B1 (fr) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
PL1608400T3 (pl) 2003-03-28 2010-11-30 Faron Pharmaceuticals Oy Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73
CA2525899C (en) 2003-05-09 2016-03-08 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US20050208627A1 (en) 2003-09-18 2005-09-22 Bowdish Katherine S Elicitation of antibodies to self peptides in mice by immunization with dendritic cells
JP2008504821A (ja) 2004-07-01 2008-02-21 バイレクシス コーポレイション ベクター・パッケージング細胞系列
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ATE462726T1 (de) * 2005-01-07 2010-04-15 Diadexus Inc Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
WO2006121991A2 (en) 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
CA2612355A1 (en) 2005-06-16 2006-12-28 Virxsys Corporation Antibody complexes
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
WO2007041694A2 (en) 2005-10-04 2007-04-12 The Johns Hopkins University Compositions and methods for treating inflammation
CA2630483C (en) * 2005-12-08 2015-05-19 Medarex, Inc. Human monoclonal antibodies to o8e
MX2008007292A (es) 2005-12-08 2008-10-17 Univ Louisville Res Found Composiciones inmunoestimuladoras y metodos.
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
US20090215084A1 (en) 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US20100028450A1 (en) 2006-01-25 2010-02-04 The Board Of Trustees Of The University Of Illinoi S Tolerogenic biodegradable artificial antigen presenting system
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
US9121853B2 (en) 2006-03-20 2015-09-01 Mayo Foundation For Medical Education And Research B7-H4 expression on tumor vasculature
CA2639070A1 (en) 2006-04-13 2007-11-01 Oncomethylime Sciences S.A. Novel tumour suppressor
WO2007124361A2 (en) 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
CA2673659A1 (en) 2006-12-27 2008-07-10 The Johns Hopkins University Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4
US20090142342A1 (en) 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) * 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
AU2008207735B2 (en) 2007-01-26 2013-10-03 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
EP2111231A4 (en) 2007-02-13 2010-12-15 Univ Northeastern METHOD AND COMPOSITIONS FOR IMPROVING IMMUNE REACTIONS
TW200938224A (en) * 2007-11-30 2009-09-16 Medarex Inc Anti-B7H4 monoclonal antibody-drug conjugate and methods of use
WO2009111315A2 (en) 2008-02-29 2009-09-11 Mayo Foundation For Medical Education And Research Methods for reducing granulomatous inflammation
WO2010102167A1 (en) 2009-03-05 2010-09-10 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
AU2010221188A1 (en) 2009-03-06 2011-10-20 Tripath Imaging, Inc. Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
US8445207B2 (en) 2009-04-07 2013-05-21 Korea Institute Of Science And Technology Genes based on thalidomide, valproic acid and methotrexate treatment for screening of drug inducing teratogenicity and screening method using thereof
US20130209514A1 (en) 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
EP2445538A2 (en) 2009-06-23 2012-05-02 University Of Miami Aptamer-targeted sirna to inhibit nonsense mediated decay
JP5769316B2 (ja) * 2009-08-06 2015-08-26 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US9005616B2 (en) 2009-08-31 2015-04-14 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
PL2699264T3 (pl) * 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
CA2845536A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170061152A (ko) * 2014-09-28 2017-06-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
KR20230035458A (ko) * 2014-09-28 2023-03-13 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
US11713487B2 (en) 2017-07-14 2023-08-01 The Regents Of The University Of California Methods of predicting transplant rejection risk

Also Published As

Publication number Publication date
US20150315275A1 (en) 2015-11-05
EP2934575A2 (en) 2015-10-28
WO2014100439A2 (en) 2014-06-26
RU2015129551A (ru) 2017-01-25
BR112015014063A2 (pt) 2018-10-30
CA2894879A1 (en) 2014-06-26
MX2015007846A (es) 2016-04-28
AU2013361231A1 (en) 2015-06-04
CA2894689A1 (en) 2014-06-26
JP2016509582A (ja) 2016-03-31
EP2934576A1 (en) 2015-10-28
HK1210027A1 (en) 2016-04-15
US9574000B2 (en) 2017-02-21
AU2013361275A1 (en) 2015-06-11
WO2014100439A3 (en) 2014-09-25
SG11201504764SA (en) 2015-07-30
WO2014100483A1 (en) 2014-06-26
CN104955475A (zh) 2015-09-30
AU2013361275B2 (en) 2016-11-24
JP2016505843A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
US9574000B2 (en) Anti-human B7-H4 antibodies and their uses
JP6120848B2 (ja) 抗ｂ７−ｈ４抗体およびその使用
KR102644544B1 (ko) Siglec-15를 위한 항체 및 이의 사용 방법
AU2014268298B2 (en) Anti-B7-H5 antibodies and their uses
RU2691428C2 (ru) Антитела к h7cr
HK1200493B (en) Anti-b7-h4 antibodies and their uses
HK1210186B (zh) 抗h7cr抗體

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150702

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid